CDK19

Across TCGA pan-cancer cohorts, CDK19 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDK19 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher CDK19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDK19 expression acts as an unfavorable survival marker.

READ, OV, and STAD are the cancer types where CDK19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	42	view →
OV	DFS	Median	All	0.112	0.542	<.001	18	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDK19–READ (OS)

Open the READ breakdown →